Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) COO Matthew E. Korenberg sold 1,157 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $105.54, for a total value of $122,109.78. Following the sale, the chief operating officer now directly owns 67,211 shares in the company, valued at approximately $7,093,448.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Ligand Pharmaceuticals Stock Performance
NASDAQ:LGND opened at $105.20 on Tuesday. The stock has a 50-day simple moving average of $95.72 and a 200 day simple moving average of $83.86. Ligand Pharmaceuticals Incorporated has a 52-week low of $49.24 and a 52-week high of $112.13. The company has a market cap of $1.89 billion, a PE ratio of 20.35 and a beta of 1.01.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.34. The company had revenue of $41.50 million during the quarter, compared to analysts’ expectations of $33.04 million. Ligand Pharmaceuticals had a net margin of 79.30% and a return on equity of 8.52%. The business’s quarterly revenue was up 57.2% on a year-over-year basis. During the same period last year, the business earned $1.10 EPS. On average, research analysts predict that Ligand Pharmaceuticals Incorporated will post 3.54 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on LGND
Institutional Trading of Ligand Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Chicago Capital LLC increased its position in shares of Ligand Pharmaceuticals by 124.3% during the 2nd quarter. Chicago Capital LLC now owns 514,946 shares of the biotechnology company’s stock worth $43,389,000 after purchasing an additional 285,350 shares during the last quarter. Ashford Capital Management Inc. bought a new position in shares of Ligand Pharmaceuticals in the first quarter valued at $14,367,000. Stephens Investment Management Group LLC increased its holdings in Ligand Pharmaceuticals by 41.0% during the fourth quarter. Stephens Investment Management Group LLC now owns 659,434 shares of the biotechnology company’s stock worth $47,097,000 after buying an additional 191,870 shares during the last quarter. F M Investments LLC acquired a new position in Ligand Pharmaceuticals during the second quarter worth $11,350,000. Finally, Norges Bank bought a new stake in Ligand Pharmaceuticals during the fourth quarter worth $7,655,000. Institutional investors own 91.28% of the company’s stock.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
See Also
- Five stocks we like better than Ligand Pharmaceuticals
- What is Forex and How Does it Work?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.